Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Starting to think its more then a Financial Issue

<< Previous

Bullboard Posts

Next >>

Comment by MiSdyngNASTYon Jul 08, 2020 11:48am

84 Views

Post# 31239612

RE:RE:Starting to think its more then a Financial Issue

That's actually really funny. And accurate.

losingmyshirt wrote: Hard to imagine why the financials are taking so long.

Ask Robert to empty his pockets onto the desk, count the change,and you have it.

Don't forget not to include the piece of gum and the Pizza Hut discount coupon in the summary as they have no cash value.